The DNA-based sensor. [Image courtesy of Level Zero Health]

基于DNA的传感器。[图片由Level Zero Health提供]

Level Zero Health announced today that it raised $6.9 million in a pre-seed funding round to support its remote, continuous monitoring platform.

零级健康公司今天宣布，它在一轮预种子资金中筹集了690万美元，以支持其远程连续监测平台。

Redalpine, a leading European venture capital firm, led the funding round. HAX (SOSV), Entrepreneur First and other industry experts also participated in the round.

红杉资本欧洲分公司（Redalpine）领投了这一轮融资，HAX（SOSV）、Entrepreneur First和其他行业专家也参与了这一轮投资。

San Francisco-based Level Zero develops remote, continuous hormone monitoring platforms using first-of-their-kind DNA-based sensors. Its technology offers an alternative to invasive blood draws, detecting hormone levels in interstitial fluid (much like a glucose sensor).

总部位于旧金山的Level Zero公司开发了基于DNA传感器的远程连续激素监测平台。其技术提供了一种替代侵入性抽血的方法，通过检测组织间液中的激素水平（类似于葡萄糖传感器）。

Level Zero combines biochemistry and nanotechnology in a sleek, minimally invasive, wearable patch. Like a CGM, it attaches to the user’s arm and delivers real-time measurements of stress and reproductive hormones. The company says it has already validated the technology in simulated samples across 98% of the human clinical range..

Level Zero 将生物化学和纳米技术结合在一个时尚、微创的可穿戴贴片中。与 CGM 类似，它贴附在用户的胳膊上，并提供压力和生殖激素的实时测量。该公司表示，其技术已经在模拟样本中验证，覆盖了 98% 的人体临床范围。

According to the company, its advancement could transform IVF, menopause and testosterone replacement therapy, among other areas of healthcare.

据该公司称，其进展可能会改变体外受精、绝经和睾酮替代疗法等其他医疗保健领域。

Level Zero plans to use its funds for R&D and team expansion as it looks to bring the product to market.

Level Zero 计划将其资金用于研发和团队扩展，以期将产品推向市场。

“Our innovative remote monitoring technology marks an enormous leap forward in hormone testing, and this funding will enable us to bring this revolutionary solution to market,” said Ula Rustamova, CEO of Level Zero Health. “This breakthrough in health technology has come about in a relatively short amount of time, but already we are seeing strong demand from customers who recognize the benefits of hormone monitoring not only because it allows patients to skip invasive and inconvenient lab tests, but also because it captures critical data inaccessible before.”.

“我们创新的远程监测技术标志着激素检测领域的一次巨大飞跃，这笔资金将使我们能够将这一革命性的解决方案推向市场，”Level Zero Health首席执行官乌拉·鲁斯塔莫娃表示。“这项健康技术的突破在相对较短的时间内实现，但客户已经看到了强劲的需求，他们认识到激素监测的好处，不仅因为它让患者可以跳过侵入性和不便的实验室测试，还因为它捕捉到了以往无法获取的关键数据。”